Skip to main content
Advertisement
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
ADVERTISEMENT
Long Kwei
PERSPECTIVE: A Randomized, Phase 3 Study of Ibrutinib-Rituximab Versus Placebo-Rituximab Combination Therapy for First-Line Treatment of Follicular Lymphoma
Background: Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma originating from germinal-center B cells.
Leonie Gordon , MD;
Simon Rule ;
Robert Chen ;
Ian W. Flinn ;
Long Kwei ;
Alvina Chu ;
Nathan Fowler ;
10/19/2020
Featured Webinar
Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications
Advertisement
Advertisement
Advertisement
Advertisement
Upcoming Events
November 6 – November 8
November 7 – November 10
November 8
November 8 – November 10
November 13 – November 16
November 14 – November 15
November 23 – November 24
December 4 – December 5
December 6 – December 7
December 9 – December 11
See Full Calendar
Advertisement
Advertisement
Advertisement